kras(g12c)

KRAS G12C inhibitor 19 is a potent KRAS G12C inhibitor that demonstrates anti-tumor activity in cellular assays and inhibits tumor growth [1].

KRAS G12C inhibitor 16 is a potent inhibitor of KRAS G12C.

KRas G12C inhibitor 1 is a compound that selectively inhibits the KRas G12C protein.

KRAS G12C Inhibitor 13 is a specific inhibitor targeting the KRAS G12C mutation.

KRAS G12C inhibitor 14 is a potent compound with an IC50 of 18 nM [1].

KRAS G12C inhibitor 15 is a potent inhibitor of the KRAS G12C protein.

KRAS G12C inhibitor 17 is a potent inhibitor of the KRAS G12C protein.

KRas G12C inhibitor 2 is a compound specifically designed to inhibit the KRas G12C mutation.

KRas G12C inhibitor 3 is a compound that specifically inhibits the KRas G12C mutation.

KRas G12C inhibitor 4 is a compound that inhibits KRas G12C.

KRAS G12C inhibitor 5 is a KRas G12C inhibitor. (Add a sentence that describes its primary function, mechanism, or application.)

KRAS G12C inhibitor 69 (Compound K09) is an inhibitor of the mutant RAS protein KRAS G12C with an IC50 of 4.36 nM. In the cell lines NCI-H358 and MIA-PACA-2, it suppresses ERK phosphorylation with IC50 values of 12 nM and 7 nM, respectively. Additionally, KRAS G12C inhibitor 69 hinders the proliferation of NCI-H358 and MIA-PACA-2 cancer cells, with IC50 values of 3.15 nM and 2.33 nM, respectively.

KRAS G12C inhibitor 18 is a potent and orally active compound that inhibits KRAS G12C, demonstrating significant anti-tumor activities.

KRAS G12C inhibitor 53 (Compound 1) is a KRAS G12C inhibitor.

KRAS G12C inhibitor 29 is an inhibitor of KRAS G12C and can be used to study cancer.

KRAS G12C inhibitor 30 is an inhibitor of KRAS G12C and can be used to study cancer.

KRAS G12C inhibitor 31 is an inhibitor of KRAS G12C that can be used to study cancer.

KRAS G12C inhibitor 33 is a KRAS G12C inhibitor used in cancer research.

KRAS G12C inhibitor 47 is a potent inhibitor of KRAS G12C (IC50: 0.172 μM). KRAS G12C inhibitor 47 exhibits p-ERK inhibition in MIA PaCA-2 cells, A549 cells with IC50 values of 0.046 μM and 69.8 μM respectively. KRAS G12C inhibitor 47 showed investigational potential against pancreatic, colorectal and lung cancers.

KRAS G12C inhibitor 50 is a KRAS G12C inhibitor (IC50: 46.7 nM).

KRAS G12C inhibitor 22 is a specific inhibitor of the KRAS G12C mutation.

KRAS G12C inhibitor 25 is an inhibitor of KRAS G12C. KRAS G12C inhibitor 25 inhibits the SOS1-assisted GDP GTP exchange activity of KRAS-G12C mutants with an IC50 value of 0.48 nM.

KRAS G12C inhibitor 34 is an inhibitor of KRAS G12C that can be used to study cancer research.

KRAS G12C inhibitor 49 is an orally active KRAS G12C inhibitor that exhibits antitumour effects.